Order Code ACRNS Acylcarnitines, Quantitative, Serum
Necessary Information
1. Patient's age is required.
2. Include family history, clinical condition (asymptomatic or acute episode), diet, and drug therapy information.
Specimen Required
Patient Preparation: Collect specimen just prior to a scheduled meal or feeding.
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.1 mL
Collection Instructions: Centrifuge and aliquot serum into plastic vial.
Useful For
Diagnosis of fatty acid oxidation disorders and several organic acidurias using serum specimens
Evaluating treatment during follow-up of patients with fatty acid beta-oxidation disorders and several organic acidurias
Method Name
Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
Reporting Name
Acylcarnitines, Quantitative, SSpecimen Type
SerumSpecimen Minimum Volume
0.04 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Frozen (preferred) | 60 days | |
Refrigerated | 21 days | ||
Ambient | 72 hours |
Reject Due To
Gross hemolysis | OK |
Gross lipemia | OK |
Gross icterus | OK |
Reference Values
≤7 days (nmol/mL) |
8 days-7 years (nmol/mL) |
≥8 years (nmol/mL) |
|
Acetylcarnitine, C2 |
2.14-15.89 |
2.00-27.57 |
2.00-17.83 |
Acrylylcarnitine, C3:1 |
<0.04 |
<0.05 |
<0.07 |
Propionylcarnitine, C3 |
<0.55 |
<1.78 |
<0.88 |
Formiminoglutamate, FIGLU |
<0.43 |
<0.08 |
<0.14 |
Iso-/Butyrylcarnitine, C4 |
<0.46 |
<1.06 |
<0.83 |
Tiglylcarnitine, C5:1 |
<0.05 |
<0.09 |
<0.11 |
Isovaleryl-/2-Methylbutyrylcarn C5 |
<0.38 |
<0.63 |
<0.51 |
3-OH-iso-/butyrylcarnitine, C4-OH |
<0.13 |
<0.51 |
<0.18 |
Hexenoylcarnitine, C6:1 |
<0.12 |
<0.10 |
<0.15 |
Hexanoylcarnitine, C6 |
<0.14 |
<0.23 |
<0.17 |
3-OH-isovalerylcarnitine, C5-OH |
<0.08 |
<0.12 |
<0.10 |
Benzoylcarnitine |
<0.13 |
<0.07 |
<0.10 |
Heptanoylcarnitine, C7 |
<0.05 |
<0.05 |
<0.06 |
3-OH-hexanoylcarnitine, C6-OH |
<0.08 |
<0.19 |
<0.09 |
Phenylacetylcarnitine |
<0.15 |
<0.22 |
<0.29 |
Salicylcarnitine |
<0.08 |
<0.09 |
<0.09 |
Octenoylcarnitine, C8:1 |
<0.48 |
<0.91 |
<0.88 |
Octanoylcarnitine, C8 |
<0.19 |
<0.45 |
<0.78 |
Malonylcarnitine, C3-DC |
<0.09 |
<0.14 |
<0.26 |
Decadienoylcarnitine, C10:2 |
<0.11 |
<0.12 |
<0.26 |
Decenoylcarnitine, C10:1 |
<0.25 |
<0.46 |
<0.47 |
Decanoylcarnitine, C10 |
<0.27 |
<0.91 |
<0.88 |
Methylmalonyl-/succinylcarn, C4-DC |
<0.05 |
<0.05 |
<0.05 |
3-OH-decenoylcarnitine, C10:1-OH |
<0.12 |
<0.12 |
<0.13 |
Glutarylcarnitine, C5-DC |
<0.06 |
<0.10 |
<0.11 |
Dodecenoylcarnitine, C12:1 |
<0.19 |
<0.37 |
<0.35 |
Dodecanoylcarnitine, C12 |
<0.18 |
<0.35 |
<0.26 |
3-Methylglutarylcarnitine, C6-DC |
<0.28 |
<0.21 |
<0.43 |
3-OH-dodecenoylcarnitine, C12:1-OH |
<0.11 |
<0.10 |
<0.13 |
3-OH-dodecanoylcarnitine, C12-OH |
<0.06 |
<0.09 |
<0.08 |
Tetradecadienoylcarnitine, C14:2 |
<0.09 |
<0.13 |
<0.18 |
Tetradecenoylcarnitine, C14:1 |
<0.16 |
<0.35 |
<0.24 |
Tetradecanoylcarnitine, C14 |
<0.11 |
<0.15 |
<0.12 |
Octanedioylcarnitine, C8-DC |
<0.25 |
<0.19 |
<0.19 |
3-OH-tetradecenoylcarnitine C14:1OH |
<0.06 |
<0.18 |
<0.13 |
3-OH-tetradecanoylcarnitine, C14-OH |
<0.04 |
<0.05 |
<0.08 |
Hexadecenoylcarnitine, C16:1 |
<0.15 |
<0.21 |
<0.10 |
Hexadecanoylcarnitine, C16 |
<0.36 |
<0.52 |
<0.23 |
3-OH-hexadecenoylcarnitine,C16:1-OH |
<0.78 |
<0.36 |
<0.06 |
3-OH-hexadecanoylcarnitine, C16-OH |
<0.10 |
<0.07 |
<0.06 |
Octadecadienoylcarnitine, C18:2 |
<0.12 |
<0.31 |
<0.24 |
Octadecenoylcarnitine, C18:1 |
<0.25 |
<0.45 |
<0.39 |
Octadecanoylcarnitine, C18 |
<0.10 |
<0.12 |
<0.14 |
Dodecanedioylcarnitine, C12-DC |
<0.10 |
<0.04 |
<0.04 |
3-OH-octadecadienoylcarn, C18:2-OH |
<0.04 |
<0.06 |
<0.06 |
3-OH-octadecenoylcarnitine C18:1-OH |
<0.03 |
<0.04 |
<0.06 |
3-OH-octadecanoylcarnitine, C18-OH |
<0.03 |
<0.05 |
<0.03 |
Method Description
To 20 mcL of serum, 6 internal standards of known concentration (d3-acetylcarnitine, d3-propionylcarnitine, d7-butyrylcarnitine, d3-octanoylcarnitine, d3-dodecanoylcarnitine, and d3-palmitoyl-carnitine) and acetonitrile for deproteinization are added. Following shaking for 30 minutes and centrifugation, the supernate is dried and then treated with n-butanolic HCl yielding the acylcarnitines, which are analyzed as their n-butylesters by electrospray ionization tandem mass spectrometry. The concentrations of the analytes are established by computerized comparison of these analytes' ion intensities to those of the closest internal standard.(Van Hove JL, Kahler SG, Feezor MD, et al. Acylcarnitines in plasma and blood spots of patients with long-chain 3-hydroxyacylcoenzyme A dehydrogenase deficiency. J Inherit Metab Dis. 2000;23(6):571-582; Miller MJ, Cusmano-Ozog K, Oglesbee D, Young S; ACMG Laboratory Quality Assurance Committee. Laboratory analysis of acylcarnitines, 2020 update: a technical standard of the American College of Medical Genetics and Genomics [ACMG]. Genet Med. 2021;23[2]:249-258)
Day(s) Performed
Monday through Friday
Performing Laboratory
Mayo Clinic Laboratories in RochesterCPT Code Information
82017
Forms
If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.